Pfizer Gets FDA Approval for Expanded Use of Breast-Cancer Treatment Tukysa
By Katherine Hamilton
Pfizer said the Food and Drug Administration approved Tukysa as a front-line maintenance treatment for people with a form of breast cancer.
Tukysa was approved in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive breast cancer following induction treatment.
The approval expands the use of Tukysa to use during an earlier stage of metastatic disease, the drug company said Wednesday. Tukysa was first approved in 2020 for metastatic breast cancer.
In a Phase 3 trial, patients treated with Tukysa showed 36% reduction in the risk of disease progression or death following induction treatment.
The safety and tolerability was generally consistent with its known safety profile, with the exception of increased severity of hepatotoxicity, a form of liver damage caused by medications, Pfizer said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
October 07, 2026 13:29 ET (17:29 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
There Are Three Paths Forward for the AI Boom. Two of Them Lead to Lower Interest Rates
United States